December 30, 2020
You can have a role in research that could change medicine forever.
Paid clinical research studies are being conducted at Heart Lung Centre to learn more about investigational medications that are not yet available to the public.
Are Clinical Trials safe?
This is a very important question. At Heart Lung Centre, all our trials are reviewed by an independent Research Ethics Committee, who ensure that our trials are as safe as possible. We are here to answer any questions.
Learn More
Do I get paid?
Our trials vary greatly in terms of time spent on the unit and the number of procedures performed. Once we have identified a suitable trial, we can inform you of the potential compensation for your participation.
Learn More
What facilities are there?
Whether you’re here for an hour or the whole day, we will endeavour to make your stay as comfortable as possible. The volunteer lounge will provide you with a space to pass the time pleasantly between assessments.
Why do you offer Clinical Trials?
Here at Heart Lung Centre we adhere to MHRA (The Medicines and Healthcare products Regulatory Agency) who are responsible for regulating the UK medical devices market. You can find out more information here.
We do not have any studies for healthy volunteers.
-
Asthma studies
Asthma Clinical Trials are to evaluate newly developed medications and new combinations of well-established medications for the treatment of asthma.
To take part in our studies you:
- Must have been diagnosed with Asthma for 12 months or more
- Must not be, pregnant, lactating or trying to conceive with your partner (if applicable)
- Must not be currently enrolled in another clinical trial
For all studies, participants are reimbursed for their time, travel and inconvenience. If you would like to find out more register your interest and we will be in touch. Or contact us on 0207 034 3341 or recruitment@heartlungcentre.com.
Even if you do not believe you may be eligible, do register your interest as new opportunities are pending.
Current studies are detailed below.
-
Asthma Study D3250C00059
This is a clinical trial to evaluate a newly developed anti-inflammatory medication for the treatment of Asthma against a placebo. The medication has been tested in previous clinical trials with volunteers with severe Asthma, no safety issues were reported and the medication was shown to significantly reduce exacerbation rates, improve lung function and symptoms.
Any medication administered, trial or placebo would be in addition to your current medication(s). This study involves 11 to 13 visits to our central London clinic over 58 weeks. No over-night stays required.
You will be paid up to £1350 (pro rata) for your time, and any inconvenience. Reasonable travel expenses will be reimbursed.
To take part in this study you:
- Must have been diagnosed with Asthma for 12 months or more
- Must be between the ages of 18 to 70
- Must use preventative Asthma medication on a stable, daily basis to manage your Asthma for at least 12 months
- Must be a non-smoker or an ex-smoker for at least 12 months
- Must not be, pregnant, lactating or trying to conceive with your partner. (If applicable)
- Must not be currently enrolled another Clinical Trial
If you believe you may be eligible to take part and would like to find out more, register your interest on /clinical-trials-request/ and we will be in touch. Or contact us to find out more on0207 034 3341or at recruitment@heartlungcentre.com .
Even if you do not believe you may be eligible, do register your interest as new opportunities are pending.
REGISTER -
Asthma Study D7552C00001
This is a randomized, double-blinded, placebo-controlled clinical trial to assess the efficacy and safety of AZD5718. No safety or tolerability issues linked to AZD5718 have yet been discovered in previous studies on healthy individuals.
In total, there will be 6 visits, plus a telephone call, over a period of up to 5 months. You will be dispensed the study medication which you will have to consume two tablets in the morning daily alongside your regular asthma medication for 12 weeks.
You will also be asked to fill out an e-diary and conduct spirometry measurements at home. Full training will be provided for this. The e-diary and spirometry measurements are to take place twice daily – in the morning after medication and in the evening.
The study includes one initial screening visit to assess your eligibility. This includes questions about your medical history, a physical assessment, vital signs, ECGs, Blood tests and Lung Function testing. If you are found to be suitable there will be a second screening visit, where you will undergo further lung function tests, vital signs and blood tests. You will also be issued, and taught how to use, an at home spirometer and your e-dairy.
You will be reimbursed for your Travel up to £50 for each visit. You will also be compensated £50 per visit for your time and inconvenience (£350 in total for the whole study.)
To take part in this study you:
- Must have been diagnosed with Asthma for 12 months or more
- Must be between the ages of 18 to 80
- Must use preventative Asthma medication on a stable, daily basis to manage your Asthma for at least 3 months
- Must have an asthma exacerbation that required a dose of oral steroids or hospitalisation within the last 12 months
- Must be a non-smoker or an ex-smoker for at least 6 months
- Must not be, pregnant, lactating or trying to conceive with your partner. (If applicable)
- Must not be currently enrolled another Clinical Trial
If you believe you may be eligible to take part and would like to find out more, register your interest on /clinical-trials-request/ and we will be in touch. Or contact us to find out more on 0207 034 3341 or at recruitment@heartlungcentre.com .
Even if you do not believe you may be eligible, do register your interest as new opportunities are pending.
REGISTER -
Asthma Study BP44551
This is a randomized, double-blinded, placebo-controlled clinical trial to assess the safety of Selnoflast. No safety or tolerability issues linked to Selnoflast have yet been discovered in previous studies on healthy individuals.
In total, there will be 8 visits over a period of up to 11 weeks.
You will be dispensed the study medication which you will have to consume one tablet in the morning (between 7-10am) and one in the evening (between 7-10pm) daily with food. You will take Selnoflast alongside your regular asthma medication for 11 weeks.
You will also be asked to fill out an e-diary. Full training will be provided for this. (The e-diary are to take place twice daily – in the morning after medication and in the evening.)
The study includes one initial screening visit to assess your eligibility. This includes questions about your medical history, a physical assessment, vital signs, ECGs, Blood tests and Lung Function testing. If you are found to be suitable there will be a second screening visit, where you will undergo further lung function tests, vital signs and blood tests. You will also be issued, and taught how to use, an at your e-dairy.
You will be reimbursed for your Travel up to £50 for each visit. You can be compensated up to £1200 for your time and inconvenience for the whole study.
To take part in this study you:
- Must have been diagnosed with Asthma for 12 months or more
- Must be between the ages of 18 to 80
- Must use preventative Asthma medication on a stable, daily basis to manage your Asthma, for at least 3 months
- Must be a non-smoker or an ex-smoker for at least 6 months
- Must not be pregnant, lactating or trying to conceive with your partner.
- Must not be currently enrolled another Clinical Trial
If you believe you may be eligible to take part and would like to find out more, register your interest on /clinical-trials-request/ and we will be in touch. Or contact us to find out more on 0207 034 3341 or at recruitment@heartlungcentre.com .
Even if you do not believe you may be eligible, do register your interest as new opportunities are pending.
REGISTER -
Asthma Study ACT18301
This is a Phase II, randomised, double-blinded, placebo-controlled clinical trial to assess the safety and efficacy of a new study drug. This drug is designed to inhibit the initiation and amplification of the asthmatic response. It has been assessed in two phase 1 studies. It was found to be well tolerated by both healthy participants and asthmatics.
In total, there will be 18 visits across 14 months.
Pre-screening: We will ask you some questions about your medical history and conduct one lung function assessment. (If you screen fail- £50 participant reimbursement)
Screening: If you pass the Pre-screening, we will complete the screening visit the same day. This includes ECG, Vital signs, blood tests and further lung function tests. (£70 participant reimbursement)
Run in Visit: You will be issued an e-diary, home spirometer and a new inhaler to replace your current asthma medication. The new inhaler is an approved asthma maintenance inhaler, but it will be a higher dose than your current one.
Randomisation: Assessments include: bloods, ECG vital signs and lung function. If the new inhaler has not significantly improved the results of one of your lung function assessments, you will be considered a candidate for the study drug and will be randomized into the trial.
Once randomised you will be brought back to the clinic every month to receive the study drug until the end of the study. The study drug will be administered via subcutaneous injection. During this time, you will remain taking the new inhaler, using the study diary and at home spirometer.
You will be reimbursed for your Travel up to £100 for each visit (upon evidence of receipts).
For your time and participation, you will also be reimbursed £70 per visit you attend (£1,260 total). NB. Participants must agree to use contraception, and refrain from donating sperm or eggs throughout the trial and for an additional 5 months after the last dose.
To take part in this study you:
- Must have been diagnosed with Asthma for 12 months or more
- Must be between the ages of 18 to 80
- Must use preventative Asthma medication to manage your Asthma for at least 1 month
- Must have had an asthma exacerbation in the last year that required oralsteroids for at least 3 days
- Must be a non-smoker or an ex-smoker for at least 6 months
If you believe you may be eligible to take part and would like to find out more, register your interest on /clinical-trials-request/ and we will be in touch. Or contact us to find out more on 0207 034 3341 or at recruitment@heartlungcentre.com.
Even if you do not believe you may be eligible, do register your interest as new opportunities are pending.
REGISTER
-
COPD studies
Chronic Obstructive Pulmonary Disease Clinical Trials are to evaluate newly developed medications and new combinations of well-established medications for the treatment of COPD.
To take part in our studies you:
- Must not be, pregnant, lactating or trying to conceive with your partner (if applicable)
- Must not be currently enrolled in another clinical trial
For all studies, participants are reimbursed for their time, travel and inconvenience. If you would like to find out more register your interest and we will be in touch. Or contact us on 0207 034 3341 or recruitment@heartlungcentre.com.
Even if you do not believe you may be eligible, do register your interest as new opportunities are pending.
Current studies are detailed below.
-
COPD Study D5988C00001
This is a clinical trial to investigate the effect of a triple-acting inhaler (Breztri/Trixeo Aerosphere) compared to a dual-acting inhaler and a placebo on exercise tolerance and breathlessness in subjects with COPD, over the course of 14 weeks.
Both the tri-acting and dual-acting inhalers are currently approved by the MHRA for the treatment of COPD and their safety profiles are well documented in this cohort.
In total there will be 7 clinic visits and one follow up telephone phone call over a period of 14 weeks.
At the first screening, your eligibility will be assessed by carrying out various tests, including: an exercise test on a stationary bike to assess your current fitness level, vital signs, ECGs, lung function tests, urine blood sampling, and COPD relevant questionnaires. You will also be provided inhaler training to ensure your technique is optimal. The screening visit, and all subsequent visits, will last between 4 - 5 hours.
If you are found eligible, you will move onto the treatment period of the study, where you will be treated with each of the triple-acting, dual-acting, and placebo inhalers separately across two-week periods, with two-week ‘washout’ periods in between, to ensure there isn’t any cross over from the drugs. After each two-week treatment period, you will be retested to measure the impact of the inhaler you’re currently using. You will also be provided with an electronic device for the duration of the study and will be asked to report your symptoms and medication use on a daily basis. Training on how to use this will be provided.
You will be provided a study inhaler (Two puffs to be self-administered twice daily am/pm) to use throughout the study. It is important to note that you will be provided a placebo inhaler at some point in the study. Additionally, all maintenance inhalers would need to be stopped throughout the study duration, but you will be free to use Salbutamol/Ventolin as needed.
You will be reimbursed for your time £100 for the screening visit, and £250 for each subsequent visit, equating to £1,675 in total. You will also be reimbursed for your travel costs up to £50 for each visit. If you believe your travel will cost more, with advance notice we can arrange the approvals for this.
To take part in this study you:
- Must have been diagnosed with COPD for 12 months or more.
- Must be aged between 40 and 80.
- Must be a Smoker or an Ex-Smoker.
- Must be using Inhaler(s) to manage your COPD.
- Must NOT have a history of a COPD exacerbation(s) that required the treatment of antibiotics and/or oral corticosteroids within the last 12 months.
- Must not be currently enrolled in another clinical trial.
If you believe you may be eligible to take part and would like to find out more, register your interest on /clinical-trials-request/ and we will be in touch. Or contact us to find out more on0207 034 3341 or at recruitment@heartlungcentre.com .
Even if you do not believe you may be eligible, do register your interest as new opportunities are pending.
REGISTER -
COPD Study GB-0895-101
This is a phase 1, first in-human, randomized, double-blind placebo-controlled study.
The aim of this study is to investigate the safety, tolerability, and immunogenicity of a new study drug. This drug is a human monoclonal antibody which blocks a pro-inflammatory pathway important in COPD pathogenesis.
This study has one initial screening visit where you will undergo several assessments to ensure you are eligible. The screening visit will be in 2 parts. Initially you will attend for consent, lung function, vitals, ECG and blood tests. If your blood results are suitable, we will invite you back for a second visit for a sputum induction.
If you are found to be eligible the study drug, or placebo, will be administered subcutaneously after which you will remain in the clinic for 4 consecutive overnight stays. After the inpatient stays have been completed you will be asked to return to the clinic once a week for 4 weeks, then once a month for 5 months, then once every few months till study completion which occurs 500 days after randomization.
During clinic visits you will undergo several assessments such as blood tests, vital signs, ECGs and lung function tests. Overall, this study is 20 visits over 500 days. You will be reimbursed for travel for up to £75 per visit upon evidence of receipts. You will be reimbursed for your time and inconvenience for up to £8,300.
Participants must agree to use contraception, and refrain from donating sperm or eggs throughout the entire length of the trial.
To take part in this study you:
- Must have been diagnosed with COPD for 12 months or more.
- Must be aged between 40 and 80.
- Must be a Smoker or an Ex-Smoker.
- Must be using Inhaler(s) to manage your COPD.
If you believe you may be eligible to take part and would like to find out more, register your interest on /clinical-trials-request/ and we will be in touch. Or contact us to find out more on 0207 034 3341 or at recruitment@heartlungcentre.com .
Even if you do not believe you may be eligible, do register your interest as new opportunities are pending.
REGISTER -
COPD Study GSK221531
This study is a Phase I, randomised, double-blind and placebo-controlled study to assess the safety and tolerability of repeat doses of this medication in participants with COPD. This is a clinical trial to evaluate the effects of newly developed anti-inflammatory medication for the treatment of COPD. It is administered via subcutaneous injection.
This medication has been tested in animals and was well-tolerated at doses higher than what you will be given in this study. This study helps to learn more about COPD and the effects of the medication. Your participation will help to understand COPD better and may help to make new treatments for people living with the same condition/disease as you.
At visit 3 and 9, which are 3 months apart (12 weeks), you will receive 4 subcutaneous injections per visit. On the days that you will be dosed, you will be required to stay in the hospital for 6 hours following the study administration.
The study has a total of 17 visits spread over 52 weeks. The study includes one initial screening visit to assess your eligibility. This includes questions about your medical history, a physical assessment, vital signs, ECG, Blood tests and Lung Function testing.
For your time and inconvenience, you will be reimbursed £100 on your first visit. If you are found to be suitable and are enrolled into the study, you will be reimbursed for up to £2425. Your travel will also be reimbursed up to £100.
To take part in this study you:
- Must have been diagnosed with COPD for 12 months or more.
- Must be aged between 40 and 75.
- Must be using Inhaler(s) to manage your COPD for at least 3 months.
If you believe you may be eligible to take part and would like to find out more, register your interest on /clinical-trials-request/ and we will be in touch. Or contact us to find out more on 0207 034 3341 or at recruitment@heartlungcentre.com .
Even if you do not believe you may be eligible, do register your interest as new opportunities are pending.
REGISTER
-
Other Studies
In addition to our asthma and COPD studies, we are also conducting research into potential new therapies for other conditions.
If you would like to find out more register your interest and we will be in touch. Or contact us on 0207 034 3341 or recruitment@heartlungcentre.com.
Even if you do not believe you may be eligible, do register your interest as new opportunities are pending.
Current studies are detailed below.
-
Erectile Dysfunction Study RestoreX
This research study is designed to evaluate the effectiveness of the RestoreX penile traction therapy (PTT) device in men who have undergone prostate surgery. Patients will be randomly divided into two groups: one group will use the RestoreX device daily for a specified period, while the other group will not use the device initially.
Throughout the study, patients will be asked to complete questionnaires assessing their sexual function and overall experience. The study will also track any changes in your health.
Participants who are initially assigned to the non-use group will have the option to start using the device at a later point in the study.
If you consent to take part in the study, during this visit we will record your concurrent conditions, and perform a physical (including an examination of the penis). You will also complete the first questionnaire. Please bring all medications you are currently using.
If you believe you may be eligible to take part and would like to find out more, contact us to find out more on 0207 034 3341 or email us at recruitment@heartlungcentre.com .
-
Ulcerative Colitis Study GA45329
This is a randomized, double-blinded, placebo-controlled clinical trial to assess the efficacy and safety of the study drug. This is a type of medicine that targets a protein called TL1A, which is naturally found in the body and is involved in causing inflammation.
The first screening visit will comprise of a series of tests including: ECG, vital signs, physical examination, blood collection, stool sample collection, and past medical history. Shortly after the screening visit, you will be asked to undergo an endoscopy prior to starting the medication.
The study comprises of 16 visits over a period of approximately 14 months. You will receive the study drug or placebo as an infusion (into the vein) for the first four times. After this, the drug will be given as a subcutaneous injection (under the skin) for the rest of the study.
You will also be dispensed an e-Diary that you will have to complete daily by providing answers of your daily symptoms. Full training will be provided on how to use the e-Diary.
Your total time in the clinical trial will depend on how your ulcerative colitis responds to the study treatment. This could range from 1 day to approximately 70 weeks, longer if you decide to participate in the optional open-label extension phase.
For your time and inconvenience, you will be reimbursed £150 for attending the screening visit. If you are found eligible and decide to enroll in the trial, you will be reimbursed to a total value of up to £840.
Your journey to and from the clinic will also be reimbursed for up to £100.
If you’re interested and would like to find out if you’re eligible, please register your interest at /clinical-trials-request/ and we will be in touch. Or contact us to find out more on 0207 034 3341 or email us at recruitment@heartlungcentre.com.
-
Crohns Disease Study GA45331
This is a randomized, double-blinded, placebo-controlled clinical trial to assess the efficacy and safety of the study drug. This is a type of medicine that targets a protein called TL1A, which is naturally found in the body and is involved in causing inflammation.
The first screening visit will comprise of a series of tests including: ECG, vital signs, physical examination, blood collection, stool sample collection, and past medical history. Shortly after the screening visit, you will be asked to undergo a colonoscopy prior to starting the medication.
The study comprises of 16 visits over a period of approximately 14 months. You will receive the study drug or placebo as an infusion (into the vein) for the first four times. After this, the drug will be given as a subcutaneous injection (under the skin) for the rest of the study.
You will also be dispensed an e-Diary that you will have to complete daily by providing answers of your daily symptoms. Full training will be provided on how to use the e-Diary.
Your total time in the clinical trial will depend on how your Crohn’s disease responds to the study treatment. This could range from 1 day to approximately 70 weeks, longer if you decide to participate in the optional open-label extension phase.
For your time and inconvenience, you will be reimbursed £150 for attending the screening visit. If you are found eligible and decide to enroll in the trial, you will be reimbursed to a total value of up to £840.
Your journey to and from the clinic will also be reimbursed for up to £100.
If you’re interested and would like to find out if you’re eligible, please register your interest at /clinical-trials-request/ and we will be in touch. Or contact us to find out more on 0207 034 3341 or email us at recruitment@heartlungcentre.com.
FAQ'S
If you want to know more about clinical trials or are considering participating in one, the following frequently asked questions describe the role of a patient and will help you understand this unique research program.
FAQ'S-
CLINICAL TRIALS, FAQ'S -
CLINICAL TRIALS, FAQ'S 
December 30, 2020Are the clinical trials safe?
-
CLINICAL TRIALS, FAQ'S 
December 30, 2020Can I take part?
-
CLINICAL TRIALS, FAQ'S 
December 30, 2020Can I choose which study I take part in?
-
CLINICAL TRIALS, FAQ'S 
December 30, 2020How much do the trials pay?
-
CLINICAL TRIALS, COVID TESTS, FAQ'S 
December 30, 2020How do I contact you?
Location
Explore beyond the Heart Lung Centre and discover Respiratory Clinical Trials and our hospital Queen Anne Street Medical Centre. Our state of the art facility offers a range of medical services, including consultants in different specialties, diagnostic tests and an operating theatre.
13-14 Fitzroy Square,
London, W1T 6AH
E: recruitment@heartlungcentre.com
P: 0207 0343341
Give us a call or email us, we endeavour to answer all enquiries within 24 hours on business days.
We are open from 8am — 5pm week days.